Report Detail
Global Cancer Biopharmaceuticals Market Size, Status and Forecast 2019-2025
- RnM3425506 |
- 16 May, 2019 |
- Global |
- 109 Pages |
- QYResearch |
- Pharma & Healthcare
Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Cancer drugs are the primary concern in terms of drug development trends.
In 2018, the global Cancer Biopharmaceuticals market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Cancer Biopharmaceuticals status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Biopharmaceuticals development in United States, Europe and China.
The key players covered in this study
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics
Market segment by Type, the product can be split into
Biologics
Biosimilars
Market segment by Application, split into
Liquid Cancers
Solid Cancers
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Cancer Biopharmaceuticals status, future forecast, growth opportunity, key market and key players.
To present the Cancer Biopharmaceuticals development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cancer Biopharmaceuticals are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Cancer Biopharmaceuticals Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Biologics
- 1.4.3 Biosimilars
- 1.5 Market by Application
- 1.5.1 Global Cancer Biopharmaceuticals Market Share by Application (2014-2025)
- 1.5.2 Liquid Cancers
- 1.5.3 Solid Cancers
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Cancer Biopharmaceuticals Market Size
- 2.2 Cancer Biopharmaceuticals Growth Trends by Regions
- 2.2.1 Cancer Biopharmaceuticals Market Size by Regions (2014-2025)
- 2.2.2 Cancer Biopharmaceuticals Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
- 3.1 Cancer Biopharmaceuticals Market Size by by Players
- 3.1.1 Global Cancer Biopharmaceuticals Revenue by by Players (2014-2019)
- 3.1.2 Global Cancer Biopharmaceuticals Revenue Market Share by by Players (2014-2019)
- 3.1.3 Global Cancer Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
- 3.2 Cancer Biopharmaceuticals Key Players Head office and Area Served
- 3.3 Key Players Cancer Biopharmaceuticals Product/Solution/Service
- 3.4 Date of Enter into Cancer Biopharmaceuticals Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Cancer Biopharmaceuticals Market Size by Type (2014-2019)
- 4.2 Global Cancer Biopharmaceuticals Market Size by Application (2014-2019)
5 United States
- 5.1 United States Cancer Biopharmaceuticals Market Size (2014-2019)
- 5.2 Cancer Biopharmaceuticals Key Players in United States
- 5.3 United States Cancer Biopharmaceuticals Market Size by Type
- 5.4 United States Cancer Biopharmaceuticals Market Size by Application
6 Europe
- 6.1 Europe Cancer Biopharmaceuticals Market Size (2014-2019)
- 6.2 Cancer Biopharmaceuticals Key Players in Europe
- 6.3 Europe Cancer Biopharmaceuticals Market Size by Type
- 6.4 Europe Cancer Biopharmaceuticals Market Size by Application
7 China
- 7.1 China Cancer Biopharmaceuticals Market Size (2014-2019)
- 7.2 Cancer Biopharmaceuticals Key Players in China
- 7.3 China Cancer Biopharmaceuticals Market Size by Type
- 7.4 China Cancer Biopharmaceuticals Market Size by Application
8 Japan
- 8.1 Japan Cancer Biopharmaceuticals Market Size (2014-2019)
- 8.2 Cancer Biopharmaceuticals Key Players in Japan
- 8.3 Japan Cancer Biopharmaceuticals Market Size by Type
- 8.4 Japan Cancer Biopharmaceuticals Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Cancer Biopharmaceuticals Market Size (2014-2019)
- 9.2 Cancer Biopharmaceuticals Key Players in Southeast Asia
- 9.3 Southeast Asia Cancer Biopharmaceuticals Market Size by Type
- 9.4 Southeast Asia Cancer Biopharmaceuticals Market Size by Application
10 India
- 10.1 India Cancer Biopharmaceuticals Market Size (2014-2019)
- 10.2 Cancer Biopharmaceuticals Key Players in India
- 10.3 India Cancer Biopharmaceuticals Market Size by Type
- 10.4 India Cancer Biopharmaceuticals Market Size by Application
11 Central & South America
- 11.1 Central & South America Cancer Biopharmaceuticals Market Size (2014-2019)
- 11.2 Cancer Biopharmaceuticals Key Players in Central & South America
- 11.3 Central & South America Cancer Biopharmaceuticals Market Size by Type
- 11.4 Central & South America Cancer Biopharmaceuticals Market Size by Application
12 International Players Profiles
- 12.1 Sanofi
- 12.1.1 Sanofi Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Cancer Biopharmaceuticals Introduction
- 12.1.4 Sanofi Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.1.5 Sanofi Recent Development
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Cancer Biopharmaceuticals Introduction
- 12.2.4 Johnson & Johnson Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.2.5 Johnson & Johnson Recent Development
- 12.3 Pfizer
- 12.3.1 Pfizer Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Cancer Biopharmaceuticals Introduction
- 12.3.4 Pfizer Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.3.5 Pfizer Recent Development
- 12.4 Novartis
- 12.4.1 Novartis Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Cancer Biopharmaceuticals Introduction
- 12.4.4 Novartis Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.4.5 Novartis Recent Development
- 12.5 Merck
- 12.5.1 Merck Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Cancer Biopharmaceuticals Introduction
- 12.5.4 Merck Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.5.5 Merck Recent Development
- 12.6 GlaxoSmithKline
- 12.6.1 GlaxoSmithKline Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Cancer Biopharmaceuticals Introduction
- 12.6.4 GlaxoSmithKline Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.6.5 GlaxoSmithKline Recent Development
- 12.7 Eli Lilly
- 12.7.1 Eli Lilly Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Cancer Biopharmaceuticals Introduction
- 12.7.4 Eli Lilly Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.7.5 Eli Lilly Recent Development
- 12.8 Agios Pharmaceuticals
- 12.8.1 Agios Pharmaceuticals Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Cancer Biopharmaceuticals Introduction
- 12.8.4 Agios Pharmaceuticals Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.8.5 Agios Pharmaceuticals Recent Development
- 12.9 Bristol-Myers Squibb
- 12.9.1 Bristol-Myers Squibb Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Cancer Biopharmaceuticals Introduction
- 12.9.4 Bristol-Myers Squibb Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.9.5 Bristol-Myers Squibb Recent Development
- 12.10 AstraZeneca
- 12.10.1 AstraZeneca Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Cancer Biopharmaceuticals Introduction
- 12.10.4 AstraZeneca Revenue in Cancer Biopharmaceuticals Business (2014-2019)
- 12.10.5 AstraZeneca Recent Development
- 12.11 Mylan
- 12.12 LEO Pharma
- 12.13 Boehringer Ingelheim
- 12.14 Alexion Pharmaceuticals
- 12.15 Elusys Therapeutics
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Cancer Biopharmaceuticals . Industry analysis & Market Report on Cancer Biopharmaceuticals is a syndicated market report, published as Global Cancer Biopharmaceuticals Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Cancer Biopharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
